Cancers, Vol. 16, Pages 1055: Comparing Molnupiravir to Nirmatrelvir/Ritonavir (Paxlovid) in the Treatment of Mild-to-Moderate COVID-19 in Immunocompromised Cancer Patients
Conclusions: In the treatment of mild-to-moderate COVID-19 in cancer patients, Molnupiravir was comparable to Nirmatrelvir/Ritonavir in preventing progression to severe disease/death and rebound events, and it had a superior safety profile.
Source: Cancers - Category: Cancer & Oncology Authors: Andrea J. Haddad Ray Y. Hachem Mohamed Moussa Ying Jiang Hiba R. Dagher Patrick Chaftari Anne-Marie Chaftari Issam I. Raad Tags: Article Source Type: research